Biomaterials for enhancing anti-cancer immunity

Current Opinion in Biotechnology

Volumn 40, Issue , 2016, Pages 1-8

  Koshy, Sandeep T ^a,b,c   Mooney, David J ^a,b  

^a HARVARD UNIVERSITY   (United States)

^b HARVARD UNIVERSITY   (United States)

^c HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMATERIALS;

ANTICANCER ACTIVITIES; CANCER IMMUNOTHERAPY; IMMUNE CELLS; THERAPEUTIC BENEFITS;

DISEASES;

BIOMATERIAL; CD137 LIGAND; CD3 ANTIBODY; CD40 LIGAND MONOCLONAL ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; LIPOSOME; MONOCLONAL ANTIBODY CD28; NANOPARTICLE; PHOSPHORYL LIPID A; POLYINOSINIC POLYCYTIDYLIC ACID; POLYPROPYLENE;

ANTIBODY RESPONSE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL FUNCTION; CELL HOMING; CELL MATURATION; CELL SURVIVAL; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; EX VIVO STUDY; HUMAN; IN VIVO STUDY; LYMPHOCYTE MIGRATION; MELANOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; TH1 CELL; TH2 CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANTIGEN PRESENTING CELL; DRUG EFFECTS; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOTHERAPY; NEOPLASM;

ANTIGEN-PRESENTING CELLS; BIOCOMPATIBLE MATERIALS; HUMANS; IMMUNOMODULATION; IMMUNOTHERAPY; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84960873837     PISSN: 09581669     EISSN: 18790429     Source Type: Journal    
DOI: 10.1016/j.copbio.2016.02.001     Document Type: Review

References (53)

1. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
2. Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature 2011, 480:480-489.
3. Sharma P., Allison J. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 2015, 161:205-214.
4. Topalian S., Drake C., Pardoll D. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015, 27:450-461.
5. Rosenberg S.A., Restifo N.P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 2015, 348:62-68.
6. Barrett D.M., Singh N., Porter D.L., Grupp S.A., June C.H. Chimeric antigen receptor therapy for cancer. Annu Rev Med 2014, 65:333-347.
7. Melief C.J.M., van Hall T., Arens R., Ossendorp F., van der Burg S.H. Therapeutic cancer vaccines. J Clin Invest 2015, 125:3401-3412.
8. Kearney C.J., Mooney D.J. Macroscale delivery systems for molecular and cellular payloads. Nat Mater 2013, 12:1004-1017.
9. Wang A.Z., Langer R., Farokhzad O.C. Nanoparticle delivery of cancer drugs. Annu Rev Med 2012, 63:185-198.
10. Singh A., Peppas N.A. Hydrogels and scaffolds for immunomodulation. Adv Mater 2014, 26:6530-6541.
11. Cheung A.S., Mooney D.J. Engineered materials for cancer immunotherapy. Nano Today 2015, 10.1016/j.nantod.2015.06.007.
12. Mehta N.K., Moynihan K.D., Irvine D.J. Engineering new approaches to cancer vaccines. Cancer Immunol Res 2015, 3:836-843.
13. Fan Y., Moon J.J. Nanoparticle drug delivery systems designed to improve cancer vaccines and immunotherapy. Vaccines 2015, 3:662-685.
14. Irvine D.J., Hanson M.C., Rakhra K., Tokatlian T. Synthetic nanoparticles for vaccines and immunotherapy. Chem Rev 2015, 115:11109-11146.
15. Chen D.S., Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013, 39:1-10.
16. Ali O.A., Huebsch N., Cao L., Dranoff G., Mooney D.J. Infection-mimicking materials to program dendritic cells in situ. Nat Mater 2009, 8:151-158.
17. Ali O.A., Emerich D., Dranoff G., Mooney D.J. In situ regulation of DC subsets and T cells mediates tumor regression in mice. Sci Transl Med 2009, 1. 8ra19.
18. Ali O.A., Tayalia P., Shvartsman D., Lewin S., Mooney D.J. Inflammatory cytokines presented from polymer matrices differentially generate and activate DCs in situ. Adv Funct Mater 2013, 23:4621-4628.
19. Ali O.A., Verbeke C., Johnson C., Sands R.W., Lewin S.A., White D., Doherty E., Dranoff G., Mooney D.J. Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants. Cancer Res 2014, 74:1670-1681.
20. Kim J., Li W.A., Choi Y., Lewin S.A., Verbeke C.S., Dranoff G., Mooney D.J. Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy. Nat Biotechnol 2015, 33:64-72.
21. Bencherif S.A., Sands R.W., Bhatta D., Arany P., Verbeke C.S., Edwards D.A., Mooney D.J. Injectable preformed scaffolds with shape-memory properties. Proc Natl Acad Sci U S A 2012, 109:19590-19595.
22. Koshy S.T., Ferrante T.C., Lewin S.A., Mooney D.J. Injectable, porous, and cell-responsive gelatin cryogels. Biomaterials 2014, 35:2477-2487.
23. Bencherif S.A., Sands R.W., Ali O.A., Li W.A., Lewin S.A., Braschler T.M., Shih T.-Y., Verbeke C.S., Bhatta D., Dranoff G., Mooney D.J. Injectable cryogel-based whole-cell cancer vaccines. Nat Commun 2015, 10.1038/ncomms8556.
24. Sandoval F., Terme M., Nizard M., Badoual C., Bureau M.-F., Freyburger L., Clement O., Marcheteau E., Gey A., Fraisse G., et al. Mucosal imprinting of vaccine-induced CD8+ T cells is crucial to inhibit the growth of mucosal tumors. Sci Transl Med 2013, 5. 172ra20.
25. Nembrini C., Stano A., Dane K.Y., Ballester M., van der Vlies A.J., Marsland B.J., Swartz M.A., Hubbell J.A. Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination. Proc Natl Acad Sci U S A 2011, 108:E989-E997.
26. Moon J.J., Suh H., Bershteyn A., Stephan M.T., Liu H., Huang B., Sohail M., Luo S., Ho Um S., Khant H., et al. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat Mater 2011, 10:243-251.
27. Li A.V., Moon J.J., Abraham W., Suh H., Elkhader J., Seidman M.A., Yen M., Im E.-J., Foley M.H., Barouch D.H., Irvine D.J. Generation of effector memory T cell-based mucosal and systemic immunity with pulmonary nanoparticle vaccination. Sci Transl Med 2013, 5. 204ra130.
28. Stephan M.T., Moon J.J., Um S.H., Bershteyn A., Irvine D.J. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat Med 2010, 16:1035-1041.
29. Zheng Y., Stephan M.T., Gai S.A., Abraham W., Shearer A., Irvine D.J. In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes. J Control Release 2013, 172:426-435.
30. Stephan S.B., Taber A.M., Jileaeva I., Pegues E.P., Sentman C.L., Stephan M.T. Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Nat Biotechnol 2015, 33:97-101.
31. Pal I., Ramsey J.D. The role of the lymphatic system in vaccine trafficking and immune response. Adv Drug Deliv Rev 2011, 63:909-922.
32. Jewell C.M., López S.C.B., Irvine D.J. In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles. Proc Natl Acad Sci U S A 2011, 108:15745-15750.
33. Reddy S.T., van der Vlies A.J., Simeoni E., Angeli V., Randolph G.J., O'Neil C.P., Lee L.K., Swartz M.A., Hubbell J.A. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 2007, 25:1159-1164.
34. Manolova V., Flace A., Bauer M., Schwarz K., Saudan P., Bachmann M.F. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 2008, 38:1404-1413.
35. John A.L.S., Chan C.Y., Staats H.F., Leong K.W., Abraham S.N. Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes. Nat Mater 2012, 11:250-257.
36. Zhuang Y., Ma Y., Wang C., Hai L., Yan C., Zhang Y., Liu F., Cai L. PEGylated cationic liposomes robustly augment vaccine-induced immune responses: role of lymphatic trafficking and biodistribution. J Control Release 2012, 159:135-142.
37. Cruz L.J., Rosalia R.A., Kleinovink J.W., Rueda F., Löwik C.W., Ossendorp F. Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8+ T cell response: a comparative study. J Control Release 2014, 192:209-218.
38. Mueller S.N., Tian S., DeSimone J.M. Rapid and persistent delivery of antigen by lymph node targeting PRINT nanoparticle vaccine carrier to promote humoral immunity. Mol Pharm 2015, 12:1356-1365.
39. de Titta A., Ballester M., Julier Z., Nembrini C., Jeanbart L., van der Vlies A.J., Swartz M.A., Hubbell J.A. Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose. Proc Natl Acad Sci U S A 2013, 110:19902-19907.
40. Hanson M.C., Crespo M.P., Abraham W., Moynihan K.D., Szeto G.L., Chen S.H., Melo M.B., Mueller S., Irvine D.J. Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants. J Clin Invest 2015, 125:2532-2546.
41. Swartz M.A., Lund A.W. Lymphatic and interstitial flow in the tumour microenvironment: linking mechanobiology with immunity. Nat Rev Cancer 2012, 12:210-219.
42. Thomas S.N., Vokali E., Lund A.W., Hubbell J.A., Swartz M.A. Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response. Biomaterials 2014, 35:814-824.
43. Jeanbart L., Ballester M., de Titta A., Corthésy P., Romero P., Hubbell J.A., Swartz M.A. Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes. Cancer Immunol Res 2014, 2:436-447.
44. Liu H., Moynihan K.D., Zheng Y., Szeto G.L., Li A.V., Huang B., Van Egeren D.S., Park C., Irvine D.J. Structure-based programming of lymph-node targeting in molecular vaccines. Nature 2014, 507:519-522.
45. Joyce J.A., Fearon D.T. T cell exclusion, immune privilege, and the tumor microenvironment. Science 2015, 348:74-80.
46. Liu H., Kwong B., Irvine D.J. Membrane anchored immunostimulatory oligonucleotides for in vivo cell modification and localized immunotherapy. Angew Chem Int Ed 2011, 50:7052-7055.
47. Kwong B., Liu H., Irvine D.J. Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy. Biomaterials 2011, 32:5134-5147.
48. Umeki Y., Mohri K., Kawasaki Y., Watanabe H., Takahashi R., Takahashi Y., Takakura Y., Nishikawa M. Induction of potent antitumor immunity by sustained release of cationic antigen from a DNA-based hydrogel with adjuvant activity. Adv Funct Mater 2015, 25:5758-5767.
49. Kwong B., Gai S.A., Elkhader J., Wittrup K.D., Irvine D.J. Localized immunotherapy via liposome-anchored anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity. Cancer Res 2013, 73:1547-1558.
50. Park J., Wrzesinski S.H., Stern E., Look M., Criscione J., Ragheb R., Jay S.M., Demento S.L., Agawu A., Licona Limon P., et al. Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. Nat Mater 2012, 11:895-905.
51. Stephan M.T., Stephan S.B., Bak P., Chen J., Irvine D.J. Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles. Biomaterials 2012, 33:5776-5787.
52. Li Y., Fang M., Zhang J., Wang J., Song Y., Shi J., Li W., Wu G., Ren J., Wang Z., et al. Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity. Oncoimmunology 2015, 10.1080/2162402X.2015.1074374.
53. Schumacher T.N., Schreiber R.D. Neoantigens in cancer immunotherapy. Science 2015, 348:69-74.